Whole-genome sequencing identifies new genetic alterations in meningiomas

Tang, Ming; Heng, Wei; Han, Lu; Deng, Jiaojiao; Wang, Yuelong; Yang, Meng; Tang, YH; Guo, Gang; Zhou, Liangxue; Tong, Aiping

doi:10.18632/oncotarget.15043

Cited by 17 publications

(14 citation statements)

References 21 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The microRNA libraries were generated from the CNE-2 cells with OE-NEAT1 or null vector, and were sequenced on a HiSeq 4000 Sequencing platform (Illumina, San Diego, CA, USA) to identify differential expressed miRNAs. The detailed experimental procedures were followed our previously studies [ 55 ]. The cDNA was sequenced on an Illumina/Solexa sequencing platform by the Beijing Biomarker Technologies Co. Ltd. (Beijing, China).…”

Section: Methodsmentioning

confidence: 99%

Long non-coding RNA NEAT1 regulates epithelial membrane protein 2 expression to repress nasopharyngeal carcinoma migration and irradiation-resistance through miR-101-3p as a competing endogenous RNA mechanism

Wang

Chen

et al. 2017

Oncotarget

View full text Add to dashboard Cite

The altered expression of long non-coding RNAs (lncRNAs) is often related to carcinogenesis, metastasis and resistance to radiation or chemotherapy. In the current study, cDNA microarray analysis found that NEAT1 expression was reduced in nasopharyngeal carcinoma (NPC) patients and that it regulated NPC progression. However, the detailed mechanisms of NEAT1 in NPC were unclear. NEAT1 repressed NPC cell growth, invasion and radiation resistance in vitro and tumor metastasis in vivo. In addition, the results of an approach integrating bioinformatics, luciferase reporter assays and RNA immunoprecipitation indicated that NEAT1 antagonized miR-101-3p through a competing endogenous RNA (ceRNA) mechanism and that the interaction between NEAT1 and EMP2 was miR-101-3p dependent. Our results showed a novel connection of NEAT1, miR-101-3p and EMP2 in NPC migration and radiation resistance.

show abstract

Section: Methodsmentioning

confidence: 99%

Long non-coding RNA NEAT1 regulates epithelial membrane protein 2 expression to repress nasopharyngeal carcinoma migration and irradiation-resistance through miR-101-3p as a competing endogenous RNA mechanism

Wang

Chen

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…TRAF7 mutations were detected in 8 tumors from ED group #3 (47%) without correlation with patient's age but with correlation with NHERF1 microlumen extent, and occurred mainly in SB location (Figure 2A,B, Table 1 and Table S1). Unlike NF2, TRAF7 mutations were missense (Q384E, N520S, Q539H, G560C, Y563C, S629T, R653Q), most having been described in meningioma, in correlation with SB location [5,18]. Mutations in other known genes involved in meningioma pathogenesis such as AKT1 (E17K) and KLF4 (P238S) were marginally involved in one midline SB tumor, each from ED group #3 ( Figure 2A,B and Table S2).…”

Section: Chordoid Meningioma Ed Groups Exhibit Distinct Gene Mutationmentioning

confidence: 97%

Mutation Status and Epithelial Differentiation Stratify Recurrence Risk in Chordoid Meningioma—A Multicenter Study with High Prognostic Relevance

Georgescu

Nanda

et al. 2020

Cancers

View full text Add to dashboard Cite

Chordoid meningioma is a rare WHO grade II histologic variant. Its molecular alterations or their impact on patient risk stratification have not been fully explored. We performed a multicenter, clinical, histological, and genomic analysis of chordoid meningiomas from 30 patients (34 tumors), representing the largest integrated study to date. By NHERF1 microlumen immunohistochemical detection, three epithelial differentiation (ED) groups emerged: #1/fibroblastic-like, #2/epithelial-poorly-differentiated and #3/epithelial-well-differentiated. These ED groups correlated with tumor location and genetic profiling, with NF2 and chromatin remodeling gene mutations clustering in ED group #2, and TRAF7 mutations segregating in ED group #3. Mutations in LRP1B were found in the largest number of cases (36%) across ED groups #2 and #3. Pathogenic ATM and VHL germline mutations occurred in ED group #3 patients, conferring an aggressive or benign course, respectively. The recurrence rate significantly correlated with mutations in NF2, as single gene, and with mutations in chromatin remodeling and DNA damage response genes, as groups. The recurrence rate was very high in ED group #2, moderate in ED group #3, and absent in ED group #1. This study proposes guidelines for tumor recurrence risk stratification and practical considerations for patient management.

show abstract

“…To further expand the young genetic landscape of meningioma, Tang et al . performed whole genome sequencing across seven tumor-normal pairs to identify somatic genetic alterations in meningioma 20 . The majority of copy number variants and single-nucleotide variants were chromatin regulators, including multiple histone members, histone-modifying enzymes, and several epigenetic regulators.…”

Section: Molecular Geneticsmentioning

confidence: 99%

“…The majority of copy number variants and single-nucleotide variants were chromatin regulators, including multiple histone members, histone-modifying enzymes, and several epigenetic regulators. Recurrent chromosomal arrangements on chromosome 22q, 6p, and 1q were detected 20 .…”

Section: Molecular Geneticsmentioning

confidence: 99%

Recent advances in managing/understanding meningioma

2018

View full text Add to dashboard Cite

Meningiomas are the most common adult primary intracranial tumor. Despite their higher incidence, there have not—until recently—been as many advances in understanding and managing meningiomas. Thus far, two broad classes of meningiomas have emerged on the basis of their mutational profile: those driven by neurofibromatosis 2 (NF2) inactivation and those with non-NF2 driver gene alterations, such as mammalian target of rapamycin and Hedgehog, Wingless/b-catenin, Notch, transforming growth factor-b receptor, mitogen-activated protein kinase, and phospholipase C pathway alterations. In addition to improvements in molecular diagnostics, advances in imaging are being studied to better predict tumor behavior, stratify risk, and potentially monitor for disease response. Management consists primarily of surgery and radiation therapy and there has been limited success from medical therapies, although novel targeted agents are now in clinical trials. Advances in imaging and understanding of the genetic makeup of meningiomas demonstrate the huge potential in revolutionizing the classification, diagnosis, management, and prognosis of meningiomas..

show abstract

Whole-genome sequencing identifies new genetic alterations in meningiomas

Cited by 17 publications

References 21 publications

Long non-coding RNA NEAT1 regulates epithelial membrane protein 2 expression to repress nasopharyngeal carcinoma migration and irradiation-resistance through miR-101-3p as a competing endogenous RNA mechanism

Long non-coding RNA NEAT1 regulates epithelial membrane protein 2 expression to repress nasopharyngeal carcinoma migration and irradiation-resistance through miR-101-3p as a competing endogenous RNA mechanism

Mutation Status and Epithelial Differentiation Stratify Recurrence Risk in Chordoid Meningioma—A Multicenter Study with High Prognostic Relevance

Recent advances in managing/understanding meningioma

Contact Info

Product

Resources

About